The Ordinary General Meeting of Shareholders of Biofarm on April 26 ended, among other things, with the approval of the distribution of the net profit achieved in 2020 and the gross dividend of 0.022 lei / share. At the same time, the OGMS approved the budget of revenues and expenditures for 2021. The Romanian drug manufacturer Biofarm (BIO) will make investments of over 47 million lei in 2021. These aim to equip the new production unit, but also the modernization of the first unit of the company.

"We started 2021 with extraordinary figures obtained after a difficult year, as a result of the pandemic context, and we continue it with ambitious objectives: we aim at a 15% increase in turnover and a 7% increase in profit. The new production unit opened this year, the first of such a scale built in Romania after 1990, contributes greatly to the increase in production and allows us to expand into new markets. In this way, we continue to consolidate our market share and remain a key player in the top companies in the local pharmaceutical industry in the Consumer Healthcare (CHC) category” said Cătălin Vicol, General Manager of Biofarm.

With a production area of ​​over 3,600 square meters, the new unit will benefit from 70% of the total investments this year for the endowment with state-of-the-art equipment and installations. The unit has a total production flow 3 times higher than the current one.

The production unit located on Logofătul Tăutul Street will also benefit from important investments: over 8 million lei will be allocated for the arrangement of office spaces, but also for technology. Part of the investment budget will be allocated to supplement the auto fleet.

Technological development is an essential pillar in the strategy of the drug manufacturer for which innovation is still the engine that supports evolution, after 100 years of activity. Biofarm has already started production in the new unit and has a complex plan for the development of new products, benefiting from the latest equipment and installations, a major investment for the future of the company.